Tirabrutinib
- Generic Name
- Tirabrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N6O3
- CAS Number
- 1351636-18-4
- Unique Ingredient Identifier
- LXG44NDL2T
- Background
Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT04947319
- Locations
- 🇺🇸
Cedar Sinai Medical Cancer, Hollywood, California, United States
🇺🇸University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸Mayo Clinic- Phoenix, Phoenix, Arizona, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04827589
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 152
- Registration Number
- NCT03100942
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸IRIS Research and Development, LLC, Plantation, Florida, United States
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany
Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 42
- Registration Number
- NCT02626026
- Locations
- 🇺🇸
Lovelace Scientific Resources, Inc., Venice, Florida, United States
🇺🇸Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 203
- Registration Number
- NCT02457598
- Locations
- 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 29
- Registration Number
- NCT02457559
- Locations
- 🇫🇷
Hopital Saint Eloi, Montpellier, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre Benite, France
🇬🇧Leicester Royal Infirmary, Leicester, United Kingdom
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01659255
- Locations
- 🇫🇷
CHU St Eloi, Montpellier, France
🇫🇷CHRU - Hopital Claude HURIEZ, Lille, France
🇫🇷Centre hospitalier Lyon Sud, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.